| Autor: |
Diez, R Asensi, Pérez, JM Salas, Léópez, A Henares, Iglesias, JM Reguera, Santis, LB Valiente de, Géóáómez, I Méóárquez, Romero, L Yunquera, Castillo, I Muéóáóñoz |
| Zdroj: |
European Journal of Hospital Pharmacy : Science and Practice; 2018, Vol. 25 Issue: Supplement 1 pA231-A232, 2p |
| Abstrakt: |
BackgroundInappropriate prescription of antimicrobials has a significant epidemiological impact, since it favours the selection of strains of resistant microorganisms.PurposeEvaluate the changes in antimicrobials or route of administration by the infectious diseases team in a third-level hospital according to a local programme.Material and methodsObservational and retrospective study. Every Monday during the study period (January to March 2017) all those patients selected by a pharmacist who meet the following inclusion criteria were: 1. Prescription of IV quinolones for more than three days. 2. Prescription of carbapenems, daptomycin, linezolid, cefepime, tigecycline and echinocandins for more than 5 days. On days 3 and 5, his doctor was informed by a reading alarm in the prescription programme of the possibility of switching quinolone to the oral route or the convenience of using these restricted antimicrobials, respectively. In the case of persistence on days 5 and 7, the pharmacist sent a semanal e-mail to a member of the infectious diseases unit (IDU) concerning the need for maintenance or not of the intravenous route, and the need to continue or not with these restricted antimicrobials, respectively. The member of the IDU decided whether the quinolone was switched from the intravenous route to the oral route or if the restricted antimicrobials were modified to others if it was considered appropriate.ResultsThe results are described in Table 1.ConclusionThe collaboration between the pharmacy unit and infectious diseases has allowed us to optimise the use of antimicrobials in our hospital. However, it is necessary to increase the awareness and training of doctors concerning the inadequate use of antimicrobials due to the risks involved and the unnecessary health costs.References and/or AcknowledgementsInfectious diseases unit.Conflict of interest: Corporate-sponsored research or other substantive relationships: Janssen, Alexion, Novartis.Abstract 6ER-005 Table 1Hospital unitsNumber of patients with inclusion criteriaNumber of changes made by a member of IDUSurgical unitsCardiovascular75Digestive116Thoracic21Maxillofacial21Plastic31Neurosurgery2510Medical unitsCardiology21Haematology12035Digestive2114Infectious diseases92Internal medicine1714Nephrology33Neumology50Neurology11Oncology43Otorhinolaryngology10Traumatology123Urology41Intensive care unit10Total250101 |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
